- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,280 | 18.06.24 16:00:43 | +0,590 | +0,67% | 88,320 | 88,370 | 87,800 | 87,690 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 969,600 | 18.06.24 08:14:43 | -6,200 | -0,64% | 971,000 | 976,600 | 969,600 | 975,800 |
